KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects ra...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2023.1611580/full |
| _version_ | 1797222326083780608 |
|---|---|
| author | Judit Moldvay Judit Moldvay József Tímár |
| author_facet | Judit Moldvay Judit Moldvay József Tímár |
| author_sort | Judit Moldvay |
| collection | DOAJ |
| description | KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects radiation sensitivity but leads also to bevacizumab and bisphosphonate resistance as well. It was highly significant that allele specific irreversible inhibitors have been developed for the smoking associated G12C mutant KRAS (sotorasib and adagrasib). Based on trial data both sotorasib and adagrasib obtained conditional approval by FDA for the treatment of previously treated advanced LUAD. Similar to other target therapies, clinical administration of KRASG12C inhibitors (sotorasib and adagrasib) resulted in acquired resistance due to various genetic changes not only in KRAS but in other oncogenes as well. Recent clinical studies are aiming to increase the efficacy of G12C inhibitors by novel combination strategies. |
| first_indexed | 2024-04-24T13:19:33Z |
| format | Article |
| id | doaj.art-908dd979913142059b60f1a5d6ccb76d |
| institution | Directory Open Access Journal |
| issn | 1532-2807 |
| language | English |
| last_indexed | 2024-04-24T13:19:33Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj.art-908dd979913142059b60f1a5d6ccb76d2024-04-04T16:24:31ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072024-01-012910.3389/pore.2023.16115801611580KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challengesJudit Moldvay0Judit Moldvay1József Tímár2National Institute of Pulmonology, Budapest, HungaryPulmonology Clinic, Szentgyörgyi A. University, Szeged, HungaryDepartment of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, HungaryKRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects radiation sensitivity but leads also to bevacizumab and bisphosphonate resistance as well. It was highly significant that allele specific irreversible inhibitors have been developed for the smoking associated G12C mutant KRAS (sotorasib and adagrasib). Based on trial data both sotorasib and adagrasib obtained conditional approval by FDA for the treatment of previously treated advanced LUAD. Similar to other target therapies, clinical administration of KRASG12C inhibitors (sotorasib and adagrasib) resulted in acquired resistance due to various genetic changes not only in KRAS but in other oncogenes as well. Recent clinical studies are aiming to increase the efficacy of G12C inhibitors by novel combination strategies.https://www.por-journal.com/articles/10.3389/pore.2023.1611580/fullKRASlung adenocarcinomaG12C mutationsotorasibadagrasib |
| spellingShingle | Judit Moldvay Judit Moldvay József Tímár KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges Pathology and Oncology Research KRAS lung adenocarcinoma G12C mutation sotorasib adagrasib |
| title | KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges |
| title_full | KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges |
| title_fullStr | KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges |
| title_full_unstemmed | KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges |
| title_short | KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges |
| title_sort | krasg12c mutant lung adenocarcinoma unique biology novel therapies and new challenges |
| topic | KRAS lung adenocarcinoma G12C mutation sotorasib adagrasib |
| url | https://www.por-journal.com/articles/10.3389/pore.2023.1611580/full |
| work_keys_str_mv | AT juditmoldvay krasg12cmutantlungadenocarcinomauniquebiologynoveltherapiesandnewchallenges AT juditmoldvay krasg12cmutantlungadenocarcinomauniquebiologynoveltherapiesandnewchallenges AT jozseftimar krasg12cmutantlungadenocarcinomauniquebiologynoveltherapiesandnewchallenges |